IONIQ Sciences: Edison Open House Healthcare 2022

IONIQ Sciences: Edison Open House Healthcare 2022

IONIQ Sciences is at the forefront of early cancer detection. IONIQ Sciences is decoding the science of the body’s earliest response to the presence of cancer.

• How is the company using bioimpedance, an old technology, in a new way to treat cancer?
• Is the purpose to highlight whether further investigations need to take place?
• Do you require a skilled operator to carry out the test and someone else to interpret it?
• What makes your cancer detection platform different and why does it have significant advantages?
• What is the impact of not submitting the patient to ionising radiation?
• What have the key business changes been since you joined as CEO in 2018?
• Tell us about your recent research and regulatory milestones.
• Are there risks of over-diagnosis with early detection?


You may also be interested in these:

TMT

Checkit – executive interview

Investment Companies

International Public Partnerships - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free